Corcept Therapeutics reported $124.49M in Net Income for its fiscal quarter ending in September of 2026.





Net Income Change Date
Acadia Pharmaceuticals USD 53.52M 22.02M Sep/2026
Alaunos Therapeutics USD -952K 54K Jun/2026
ANI Pharmaceuticals USD 35.15M 10.44M Sep/2026
Ardelyx USD -16.72M 20.88M Jun/2026
Aurora Cannabis CAD -4.03M 67.07M Jun/2026
BioMarin Pharmaceutical USD -122.83M 167.59M Sep/2026
Bristol-Myers Squibb USD 2.16B 1.16B Sep/2026
Canopy Growth CAD -14.58M 142.54M Jun/2026
Corcept Therapeutics USD 124.49M 82.35M Sep/2026
Eli Lilly USD 7.1B 301M Jun/2026
J&J USD 210M 5.32B Sep/2026
Knight Therapeutics CAD -3.79M 8.83M Sep/2025
Lexicon Pharmaceuticals USD -15.53M 2.76M Dec/2025
Merck USD 5.07B 6.4B Sep/2026
Nektar Therapeutics USD -44.9M 8.82M Mar/2026
Novartis USD 1.2B 2.06B Sep/2026
Novartis USD 1.2B 1.95B Sep/2026
Omeros USD -32.23M 23.81M Sep/2024
Pfizer USD 3.24B 3.49B Sep/2026
Supernus Pharmaceuticals USD -58.37M 56.08M Jun/2026
TG Therapeutics USD 55.46M 47.68M Sep/2026